Clinical Trial Detail

NCT ID NCT03334617
Title Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors AstraZeneca
Indications

lung non-small cell carcinoma

Therapies

AZD9150 + Durvalumab

Durvalumab + Olaparib

Cediranib + Durvalumab

Durvalumab + Vistusertib

Durvalumab + Trastuzumab deruxtecan

AZD6738 + Durvalumab

Age Groups: adult senior

Additional content available in CKB BOOST